Development of a New Specific Immunosuppressive Monoclonal Antibody to Advance Transplantation

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1113563

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Current nonspecific immunosuppressive agents compromise post transplant protective responses, including the anti-tumour effect of a bone marrow transplant. We have developed an antibody (3C12C), that targets CD83 on activated dendritic cells as a new, more specific, immunosuppressive strategy. We will work with our commercial partner to develop the patented antibody as a new imunosuppressive agent, which retains anti-viral and anti-cancer responses. This would be a major advance for patients.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2018

Funding Scheme: Development Grants

Funding Amount: $736,300.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibody therapy | antigen presenting cells | immunosuppression | transplantation | transplantation tolerance

Related Links